If so, recognition of gay women is more accurate, study suggests

Yale research shows FDA ahead of other regulators in the approval process

Three cups linked to 10% lower odds of dying from typical causes, federal study finds

Small number of Tysabri users develop rare but potentially fatal infection

Only 1 in 4 Sunscreens Effective and Safe: Report Sharp Drop in Maternal Deaths: U.N. One-Third of Adults Worldwide Have High Blood Pressure: WHO /div

'Superbug' then spreads to regional facilities, Scottish study suggests

Geared toward siblings of kids with the disorder, but experts question precision of the exam

The U.S. Food and Drug Administration today expanded the use for the FilmArray Respiratory Panel, the first test that can simultaneously detect both viral and bacterial causes of respiratory infection from a single sample.

The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation procedure” to treat chronic cerebrospinal venous insufficiency (CCSVI).

Today, the U.S. Food and Drug Administration announced that it is seeking public comment on a proposal encouraging manufacturers to consider the safety of children in the design of new X-ray imaging devices. In the draft guidance, FDA is recommending that manufacturers design new X-ray imaging devices with protocols and instructions that address use on pediatric patients.

The U.S. Food and Drug Administration issued its final rule on sterility testing, amending the requirements for most licensed biological products.

On April 30, the U.S. Food and Drug Administration today allowed marketing of the first surgical instrument set that can be assembled and disassembled inside the body during surgery. The Percutaneous Surgical Set is intended to be used during minimally invasive laparoscopic abdominal surgery, in which a camera and surgical instruments are inserted through one or more small incisions (surgical cuts into body tissue) in the abdomen.

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.